Trials / Completed
CompletedNCT06449352
Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost
Effect of the Addition of Netarsudil 0.02% vs. Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Westlake Eye Specialists · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Netarsudil | netarsudil 0.02% |
| DRUG | Brimonidine | brimonidine 0.1% |
Timeline
- Start date
- 2024-06-13
- Primary completion
- 2025-09-22
- Completion
- 2025-09-22
- First posted
- 2024-06-10
- Last updated
- 2025-10-22
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06449352. Inclusion in this directory is not an endorsement.